Pharmacyclics is a clinical-stage biopharmaceutical company focusing on discovering, developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The company currently has three candidates in clinical development and several molecules in preclinical development, and has a license agreement with the University of Texas to develop and commercialize porphyrins; expanded porphyrins, such as motexafin gadolinium; and other porphyrin-like substances. It also has a collaboration and license agreement with Servier. For more information visit the company’s Web site at www.pharmacyclics.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: